

# ASX ANNOUNCEMENT

20 April 2023

## CLEANSING NOTICE UNDER SECTION 708A(5)(e)

Between 13 April 2023 and 20 April 2023, Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) issued 65,334 new fully paid Ordinary Shares (**New Shares**) to investors raising \$703,341. The issue of New Shares is as a result of the conversion of 33,334 unlisted Options exercisable at \$11.50 each and 32,000 unlisted Options exercisable at \$10.00 each.

### Details of the securities issued

Class of securities:	Fully paid ordinary shares
ASX code:	AVR
Dates of the issues:	13 April 2023, 14 April 2023 and 20 April 2023
Total number of securities issued:	65,334

Anteris gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the **Corporations Act**) that:

1. the New Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (b) section 674 of the Corporations Act;
3. as at the date of this notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

**ENDS**

#### Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

#### Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E [info.au@anteristech.com](mailto:info.au@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga



**About Anteris Technologies Ltd (ASX: AVR)**

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

**Authorisation and Additional information**

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

**For more information:****Investor contact**

Deanne Curry

GRACosway

E: [investors@anteristech.com](mailto:investors@anteristech.com)

M: +61 414 388 997

**Media contact**

Nick Howe

GRACosway

[nhowe@gracosway.com.au](mailto:nhowe@gracosway.com.au)

M: +61 407 183 221

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)

LinkedIn: <https://www.linkedin.com/company/anteristech>